Results 201 to 210 of about 64,054 (239)
Neurological Immune Related Adverse Events Associated With Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook [PDF]
Immune checkpoint inhibitor (ICI) therapy has revolutionized the management of various cancers with previously poor prognosis. Despite its great efficacy, the therapy is associated with a wide spectrum of immune-related adverse events (irAE) including neurological symptoms which can affect all parts of the central and peripheral nervous system.
Imke Satzger +2 more
exaly +4 more sources
Neurological Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors: A Review of the Literature [PDF]
Abstract Immune checkpoint inhibitors (ICIs) have made a breakthrough in cancer therapy. Patients treated with ICIs may develop immune‐related adverse events (irAEs) due to the upregulated activity of the immune system. With the increasing use of ICIs, irAEs are more frequently reported and have become important challenges in many ...
Hongzhi Guan, Jiawei Wang, Siyuan Fan
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The Role of Immune Checkpoint Therapy in Propagating Neurologic Immune-Related Adverse Events
Neurology, 2021In 2010, a novel agent, ipilimumab, demonstrated improved survival rates in patients with previously untreatable metastatic melanoma.1 Ipilimumab was approved by the Food and Drug Administration in 2011 and launched a class of pharmaceuticals that would come to be known as immune checkpoint inhibitors (ICIs).
Tova, Gardin, Erin E, Longbrake
openaire +3 more sources
Cancer is a leading cause of morbidity and mortality worldwide. The development of immune checkpoint inhibitors (ICI) has revolutionised cancer therapy, and patients who were previously incurable can now have excellent responses. These therapies work by blocking inhibitory immune pathways, like cytotoxic T lymphocyte-associated protein 4 (CTLA-4 ...
Sudarshini Ramanathan, Magdalena Lerch
exaly +3 more sources
Neurological immune-related adverse events of ipilimumab
Practical Neurology, 2013Ipilimumab enhances the T lymphocyte mediated immune response to both tumour cells and healthy tissue, improving survival in patients with metastatic melanoma but also leads to more immune-related adverse events (irAEs) than previously used treatments, such as dacarbazine.
Ilja, Bot +3 more
openaire +2 more sources
Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition
Current Oncology Reports, 2019This review highlights the spectrum of neurologic adverse events seen with use of immune checkpoint inhibitors (ICIs), their potential mechanisms, the treatments undertaken, and the clinical outcomes.The advent of ICIs has revolutionized cancer therapy. Neurologic adverse events (NAEs) are rare but clinically significant complication of ICIs.
Peter Chei-Way, Pan, Aya, Haggiagi
openaire +2 more sources
Neurology, 2023
Neurologic immune-related adverse events (n-irAEs) reportedly occur in up to 8% of patients treated with immune checkpoint inhibitors (ICIs) of all age groups. We investigated the association between age and n-irAEs in patients treated with ICIs and examined the effect of n-irAEs on survival outcomes in a large cohort of patients with melanoma.We ...
Jack Pepys +11 more
openaire +2 more sources
Neurologic immune-related adverse events (n-irAEs) reportedly occur in up to 8% of patients treated with immune checkpoint inhibitors (ICIs) of all age groups. We investigated the association between age and n-irAEs in patients treated with ICIs and examined the effect of n-irAEs on survival outcomes in a large cohort of patients with melanoma.We ...
Jack Pepys +11 more
openaire +2 more sources
Neurological immune-related adverse events of immune-checkpoint inhibitors: an updated review
La Presse MédicaleImmune checkpoint inhibitors (ICIs) have transformed cancer therapy across multiple tumor types and disease stages. By reinvigorating antitumor immune responses, these agents may also lead to the emergence of immune-related adverse events (irAEs), including a distinct spectrum of neurological toxicities. Although rare, neurological irAEs are clinically
Alberto, Picca, Dimitri, Psimaras
openaire +2 more sources
Journal of Clinical Oncology, 2018
3084Background: Neurologic irAEs are uncommon but potentially fatal toxicities of immune checkpoint blockade (ICB).
Bianca Santomasso +10 more
openaire +1 more source
3084Background: Neurologic irAEs are uncommon but potentially fatal toxicities of immune checkpoint blockade (ICB).
Bianca Santomasso +10 more
openaire +1 more source

